Abstract:OBJECTIVE To investigate and analyze the clinical manifestations, classification, therapeutic approaches and follow-up of myasthenia gravis (MG) in children in order to improve its management and prognosis. METHODS Clinical information of 135 children with MG, who were diagnosed between January 1993 to January 2008, were collected and retrospectively analyzed. And prospective following-up of these patients were conducted. RESULTS Among the 135 cases, 59 were males and 76 females, giving the ratio of M/F around 1:1.3. Totally, 115 cases (85.2%) were type I MG (ocular type), of which only 4.2% developed to generalized type during the subsequent clinical course. Type II MG (generalized type)was found in 18 cases (13.4%) and type III MG in two cases(1.5%). The onset age ranged from 5 month to 15 years, with 50.3% before three years and 80.7% before seven years. Upper respiratory tract infection was presented in 26.7% (36/135) of the sick children before the onset of MG. Among the 106 children being followed up, recurrence of the disease identified in 50.9% and the number of relapse ranged from 1 to 9. Altogether, 40.19% (43/106) of the cases were positive for anti-acetylcholine receptor antibodies (AchR-Ab) on the initial examination, and the AchR-Ab postitive rate showed no difference among different clinical subtypes and states. However, during the follow-up, 53% (9/17) of the recurrent cases, who were negative at the first onset, turned to be positive, and 37.97% (30/79) were positive for repetitive nerve stimulation in electromyogram test. There were 71 % (45/63) of all the cases showed reduced levels of CD4+ and/or CD3+ and/or CD8+. Thymus proliferation was found in 5.93% (8/135) through CT scan and thymoma in 1.48% (2/135). Steroids and anti-cholinesterase administration were effective in most cases with good prognosis. CONCLUSION Childhood MG, mainly type I, is relatively common in China, with specific characteristics which are different from western patients or adult MG in morbidity, sex distribution, progress, laboratory examination and treatment. The prevalence of myasthenia gravis crisis and mortality rate in MG children is low, and few are accompanied with thymoma. Most MG cases have a satisfied prognosis and few have neuropsychic sequela.

The correlation between the expression of AIRE, Tfh and Tfr cells and clinical severity in myasthenia gravis patients

Non-neuronal cholinergic activity is potentiated in myasthenia gravis

Study of circulating Th17 cells and associated cytokines in myasthenia gravis

[Clinical Characteristics and Follow-Up Management of 135 Children with Myasthenia Gravis].

Augmentation Of Circulating Follicular Helper T Cells And Their Impact On Autoreactive B Cells In Myasthenia Gravis

Circulating Regulatory T Cells and B Cell-Activating Factor Receptor on B Cells in Patients with Myasthenia Gravis

The Change and Relevant Significance of Th1/Th2/Th17 Cytokines in Myasthenia Gravis

Decrease of CD4+CD25highFoxp3+ regulatory T cells and elevation of CD19+BAFF-R+ B cells and soluble ICAM-1 in myasthenia gravis

Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis

Detection and Clinical Significance of Serum Autoantibodies in Patients with Myasthenia Gravis

Comparison of Peripheral Blood Regulatory T Cells and Functional Subsets Between Ocular and Generalized Myasthenia Gravis

Clinical significance of serum antibodies in different types of myasthenia gravis

Circulating CD45RA-Foxp3++ Treg cells serve as a biomarker for predicting minimal clinical manifestations status of myasthenia gravis

Associated Hyperthyroidism in Myasthenia Gravis

[Distribution Characteristics and Correlation Analysis of Antibody Detection Value in Myasthenia Gravis].

Macrophage migration inhibitory factor: A noval biomarker upregulates in myasthenia gravis and correlates with disease severity and relapse

Circulating Th1/17 cells serve as a biomarker of disease severity and a target for early intervention in AChR-MG patients

The Significance of Serum Anti-Titin Antibodies and Anti-Acetylcholine Receptor Antibodies in Patients with Myasthenia Gravis

Autoimmune thyroid disease and myasthenia gravis: a study bidirectional Mendelian randomization

Dynamic study of circulating CD_4~+CD_(25)~(high) T cells in myasthenia gravis

The susceptibility of Aire−/− mice to experimental myasthenia gravis involves alterations in regulatory T cells